Platelets are critical for haemostasis, however inappropriate activation can lead to the development of arterial thrombosis, which can result in heart attack and stroke. ADP is a key platelet agonist that exerts its actions via stimulation of two surface GPCRs (G-protein-coupled receptors), P2Y 1 and P2Y 12 . Similar to most GPCRs, P2Y receptor activity is tightly regulated by a number of complex mechanisms including receptor desensitization, internalization and recycling. In the present article, we review the molecular mechanisms that underlie P2Y 1 and P2Y 12 receptor regulation, with particular emphasis on the structural motifs within the P2Y 12 receptor, which are required to maintain regulatory protein interaction. The implications of these findings for platelet responsiveness are also discussed.
Introduction
P2Y receptors are a superfamily of GPCRs (G-proteincoupled receptors), which comprises P2Y 1 , P2Y 2 , P2Y 4 , P2Y 11 , P2Y 12 , P2Y 13 and P2Y 14 , each displaying differential activity to a range of pyrimidines and purines [1, 2] . The role of ADP has been well established as a critical regulator of platelet function, exerting its effects via binding to P2Y 1 and P2Y 12 receptors [3] [4] [5] . Downstream effects of purinergic receptor activation have been studied extensively in relation to platelet aggregation, shape change and dense granule secretion, as summarized in Figure 1 [3, 6] . ADP acting via P2Y 1 initiates platelet aggregation and platelet shape change [7] , whereas activation of P2Y 12 results in amplification, sustained aggregation and secretion [6, 8] . In addition to amplification of P2Y 1 -mediated platelet responses [9] , P2Y 12 plays an essential role in potentiating platelet responses initiated by other important platelet activators such as thrombin and thromboxane [6, 10] and is therefore, a critical regulator of haemostasis and thrombosis. Pharmacological blockade of P2Y 12 is a powerful antiplatelet strategy in the treatment and prevention of arterial thrombosis associated with coronary atherosclerosis. Clopidogrel, prasugrel and ticagrelor are potent inhibitors of P2Y 12 with efficient antithrombotic activity. In the present article, we look at the advances made in understanding the molecular mechanisms of P2Y receptor regulation in physiology and disease, with specific emphasis on recent findings relating to the molecular regulation of P2Y 12 receptor traffic.
Regulation of ADP receptor responsiveness in human platelets
Work from our laboratory [11] [12] [13] and others [14] has indicated that responses to ADP are regulated in human platelets in order to minimize inappropriate platelet recruitment and activation at the site of a growing thrombus. There is still some dispute regarding the molecular mechanisms underlying these processes. Work from our research group has demonstrated that both the P2Y 1 and P2Y 12 receptor desensitize following the addition of ADP [13] . This work conflicts with others who have shown that platelet refractoriness to ADP is caused by selective desensitization of the P2Y 1 receptor, whereas the P2Y 12 receptor remains functional and retains its ability to induce ADP-dependent amplification of platelet aggregation induced by other agonists [15, 16] . The discrepancies between these findings remain unclear although it may be explained by experimental differences, such as the agonists used to promote receptor desensitization {ADP compared with the non-hydrolysable analogue ADPβS (adenosine 5 -O-[β-thio]diphosphate)} and in the type of tag used in cell expression studies (haemagglutinin compared with green fluorescent protein).
Further efforts have aimed to characterize the molecular regulators of P2Y receptor desensitization. Studies from our laboratory have shown that both the P2Y 1 and P2Y 12 receptor rapidly desensitize in human platelets by differential kinase-dependent mechanisms [11, 13] . This work has shown that P2Y 1 responses desensitize in a PKC (protein kinase C)-dependent manner, whereas P2Y 12 responses desensitize independent of PKC but require GRKs (G-protein receptor kinases). Studies in cell lines have shown that GRK2 and GRK6-dependent phosphorylation of the P2Y 12 receptor is required for arrestin association [13, 17] . Interestingly, a recent study in arrestin-2-and arrestin-3-deficient mice has indicated that neither P2Y 1 nor P2Y 12 function in platelets is altered by deficiency of these regulatory proteins AC, adenylate cyclase; CalDAG-GEF, calcium-and DAG-bound guanine nucleotide exchange factor; DAG, diacylglycerol; MLC-P, phosphorylated myosin light-chain; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; PLC, phophoslipase C; VASP-P, phosphorylated vasodilator-stimulated phosphoprotein. [18] . Although these observations may indicate possible redundancy between arrestin isoforms, the findings of this study imply that these proteins may only play a minor role in P2Y receptor regulation [18] .
Following removal of desensitizing agonist there is a rapid resensitization of both P2Y 1 and P2Y 12 receptor responsiveness in human platelets [11] . Until recently there was little evidence of platelet purinergic receptor traffic. Both P2Y 1 and P2Y 12 receptors internalize in human platelets following agonist addition and then recycle back to the cell membrane following agonist removal, albeit with different kinetics [11, 19] . Blockade of receptor internalization or subsequent recycling results in attenuation of receptor resensitization [11] . Further studies from our research group and others [15, 16, 19, 20] have begun to define the molecular regulators and structural determinants that regulate P2Y 12 receptor traffic and function that may play a critical role in maintaining platelet ADP responsiveness that is the focus for the remainder of the present review.
P2Y 12 trafficking
The molecular mechanisms that underlie P2Y 12 receptor traffic have been extensively studied by our laboratory using both platelet and mammalian cell line approaches [13, [19] [20] [21] [22] . In the present article, the term trafficking relates to agonist-and agonist-independent internalization, subsequent intracellular sorting and recycling back to the cell surface. These studies have revealed that the P2Y 12 receptor follows the canonical trafficking pathway that involves receptor phosphorylation, arrestin recruitment followed by internalization via clathrin-coated pits and rapid recycling back to the cell surface. In addition, through mutation analysis and identification of novel P2Y 12 receptor variants, we and others have gathered key structure-function information relating to P2Y 12 [19, 20, 32] .
Molecular regulators of agonist-dependent P2Y 12 receptor internalization and recycling
The P2Y 12 receptor, similarly to P2Y 1 , internalizes via clathrin-and dynamin-mediated endocytosis [17] . These receptors appear to sort into distinct membrane clathrincoated pits, an observation that has been reported for other GPCRs [23] . The mechanisms underlying P2Y 12 receptor internalization are complex and, as with receptor desensitization, are mediated in part by GRKs and arrestin but also involves an interaction between NHERF (Na + /H + exchanger regulatory factor)/arrestin as outlined below [17, [20] [21] [22] . We have also recently demonstrated a role for the small GTP-binding protein ARF6 (ADP-ribosylation factor 6) in the internalization of P2Y 12 receptors in human platelets, with activation of P2Y 12 receptors stimulating ARF6 activity [22] . ARF6 subsequently regulates Nm23-H1, an NDP (nucleoside diphosphate) kinase to facilitate dynamin-dependent fission of clathrin-coated vesicles. Cell line studies have shown that following internalization, the P2Y 12 receptor undergoes rab5-dependent trafficking to a sorting compartment through which it is rapidly recycled The P2Y 12 protein sequence comprises 342 amino acids with a conserved amino acid sequence pattern within its TM domains (residue circles in red) typical of class A rhodopsin family GPCRs. Two N-linked glycosylation sites exist, asparagine residues (Asn 6 and Asn 13 ) indicated in orange, which are thought to impact receptor signalling. Geneotyping of platelets derived from patient cohorts presenting with a bleeding phenotype have revealed defects in the P2Y 12 protein sequence, which have been reported to impact receptor function. The positions of these mutations are highlighed in blue and documented in Table 1 .
Various motifs exist within the C-terminal tail of the receptor. At the proximal C-terminal region a potential amphipathic helix 8 (green shaded box) is predicted, with the cysteine residue (Cys 315 ) forming a possible anchoring palmitoylation site. The extreme C-terminal region contains a putative type I PDZ binding motif (ETPM, red shaded box) with a potential internal PDZ ligand (ATSL, red shaded box).
back to the cell surface in a rab4/11-dependent manner [M.R. Cunningham, S.P. Nisar, A.E. Cooke, E.D. Emery and S.J. Mundell, unpublished work] . This is in contrast with P2Y 1 receptors that recycle via a slow recycling pathway that is regulated by the endocytic sorting protein SNX1 (sorting nexin 1) [24] . This work further highlighted the differential trafficking fates of P2Y 1 and P2Y 12 . Following prolonged exposure to ADP, the P2Y 1 , but not P2Y 12 , receptor was shown to downregulate by undergoing degradation.
Structural determinants and their protein-binding partners required to maintain P2Y 12 receptor activity
Some progress has been made in investigating the impact of distinct sites within the P2Y 12 protein sequence that are important for supporting protein interaction in the regulation of P2Y 12 receptor trafficking and activity. The P2Y 12 protein sequence is composed of 342 amino acids with a conserved amino acid sequence pattern within its TM (transmembrane) domains typical of class A rhodopsin family GPCRs [25] , as detailed in Figure 2 (conserved residues circled in red).
Genotyping of platelets derived from patient cohorts presenting with a bleeding phenotype have led to the identification of a number of P2Y 12 defects (Table 1) .
Although a number of studies identified patients where no functional P2Y 12 receptor was expressed [26] [27] [28] , Table 1 lists defects where expression of the receptor is unaffected but where genetic defects having an impact on receptor function have been described. The positions of these patient mutations are also shown in the snake plot of P2Y 12 in Figure 2 (residues indicated in blue). For example, a patient documented to have multiple defects within the P2Y12 gene [R256Q/R265W within TM6/ECL (extracellular loop) 3] displayed a reduction in platelet aggregation owing to defective P2Y 12 signal transduction [29] . The importance of these residues in P2Y 12 function has since been investigated further in a yeast model system, using homology and docking models to determine their importance in ADP receptor interaction given their close proximity to the ligand binding pocket [30] . Interestingly, the identification of another patient with a critical point mutation within this same region, position P258T, observed similar reduction in platelet aggregation [31] . Another defect identified (position K174E within ECL2) was found to markedly impair both ligand binding and signal transduction [32] . This lysine residue at position 174 resides adjacent to a critical cysteine residue (Cys 175 ), which is thought to be important for ADP binding [33, 34] . Therefore the proximity of the K174E mutation to position Cys 175 might explain the effects observed on P2Y 12 12 has also identified critical points within the protein that regulate receptor function. For example, two N-linked glycosylation sites exist within the receptor (Asn 6 and Asn 13 , highlighted in orange in Figure 2) ; however, unlike studies investigating other GPCRs expressed in platelets such as PAR (proteinaseactivated receptor), where roles for glycosylation have been implicated in regulation of surface expression [35] , these sites within P2Y 12 were found to impact signal transduction [36] .
Also present within P2Y 12 is a putative type I PDZ binding motif (ETPM) at the extreme C-terminus of the protein sequence [19, 20] , as indicated in Figure 2 (red shaded box) . PDZ binding motifs within GPCRs have been shown to influence intracellular sorting, signalling, internalization and trafficking through interaction with various PDZ proteins [37] . This sequence within P2Y 12 has been demonstrated to facilitate receptor internalization and traffic back to the cell surface [19, 20] . The identification of variant P2Y 12 (P341A) in a patient population presenting with a mild bleeding phenotype reaffirmed the importance of the integrity of this motif to the regulation of P2Y 12 [19] . This work identified that disruption of the PDZ ligand resulted in impaired resensitization to ADP owing to compromised receptor traffic.
A proteomic screen carried out by our laboratory has subsequently identified a series of binding partners that specifically interact with the C-terminus of P2Y 12 , which include the NHERF isoforms [20] . Interestingly, a point mutation within the PDZ ligand (P341A) resulted in an increase in the number of putative binding partners (M.R. Cunningham and S.J. Mundell, unpublished work). This result would imply that the integrity of the PDZ ligand is essential for recognition by a specific subset of PDZ domaincontaining proteins that regulate receptor function.
As stated above, NHERF protein isoforms have recently been shown, similar to the P2Y1 receptor [38, 39] , to bind specifically to the C-tail PDZ ligand of P2Y 12 [20] . These proteins have now been shown to regulate the surface expression and activity of numerous GPCRs [40] . Agonist addition increases P2Y 12 /NHERF association that is required for agonist-stimulated receptor internalization [20] . Further study revealed that this agonist-dependent association of receptor with NHERF was actually PDZ ligand-independent and required arrestin-receptor interaction [20] . This study was therefore the first to directly demonstrate arrestindependent recruitment of NHERF1 to a receptor following agonist treatment. The in vivo significance of the NHERF-P2Y 12 interaction is currently under investigation in NHERF isoform knockout mice within our laboratory.
As stated above the PDZ motif is also required for efficient endosomal sorting of the P2Y 12 receptor back to the cell surface [19] . Recent studies have revealed that mutation within the PDZ ligand (P341A) leads to differential interactions with endocytic sorting proteins leading to intracellular retention of receptor [19] . The ability of other PDZ-interacting proteins to bind to P2Y 12 and regulate receptor function is currently under investigation.
Examination of the C-terminal sequence of P2Y 12 has revealed a possible internal PDZ ligand (position 319-322, ATSL) not too dissimilar to that observed in the Cterminal region of the ET A (endothelin A) receptor [41] . In addition, further analysis of the protein sequence has identified a region at the proximal C-terminal region of P2Y 12 (position 301-313, KSFRNLISML with a possible anchoring cysteine palmitoylation site at position 315), which may form a highly conserved amphipathic eighth helix (shown in Figure 2 ). For other GPCRs, this region has been shown to be critical for activation of G αq -dependent signalling [42] or phosphorylation by GRKs [43] . Given that P2Y 12 does not signal via G αq , this region may serve an alternative role in receptor function. An examination of these regions as functional motifs in the regulation of P2Y 12 activity is currently underway.
Conclusions and perspectives
It is now well established that P2Y 12 receptor stimulation promotes platelet activation and thereby plays a central role in maintaining the physiological integrity of the vascular system while also playing a major role in the pathological development of thrombosis. As outlined in the present review, activity of this receptor is tightly regulated by the binding of a specific set of regulatory proteins that recognize and interact with unique motifs located on the receptor. Although continuing efforts are aimed at identifying further proteins that interact with this receptor and regulate receptor activity, the challenge is now to fully characterize the biological importance of these regulatory proteins to platelet P2Y 12 receptor reactivity in vivo and assess their role in thrombus formation. 
